Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

Nuclera raises $42.5M in first close of Series B for desktop protein printer

publication date: Feb 18, 2022
author/source: Nuclera


Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, announce that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter.

Nuclera’s ground-breaking protein printing technology has attracted many new and existing institutional and strategic investors in this financing round including M&G,Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh.

Nuclera’s eProtein™ desktop bioprinter is a breakthrough rapid protein prototyping and discovery platform that enables protein printing in just 24 hours, significantly faster than existing methods of protein synthesis. The eProtein bioprinter is powered by the company’s eDrop™ digital microfluidic technology - a core enabling technology borne out of the company’s strategic partnership with E Ink. The technology has gained significant traction with customers in the pharmaceutical, biotech, agribiotech, and synthetic biology industries, which are already working with Nuclera to accelerate their innovation pipelines.

The eProtein desktop bioprinter will initially screen and print proteins for research and drug discovery customers, and the funding will also fast-track the company’s march towards developing an all-encompassing proteomics platform. This will provide Nuclera’s eProtein customers with an instrument that will unify protein expression and characterization. The all-in-one platform will increase scientific reproducibility, accelerate drug discovery, and contribute to the ever-expanding bio-economy.

“There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,” said Michael Chen, Co-founder and CEO of Nuclera. “Our eProtein desktop bioprinter makes it easy for scientists to access the proteins they need in a single day rather than the weeks, months, or even years it currently takes. The new financing and partners we are announcing today is a strong vote of confidence in our mission to increase the accessibility of the drug discovery and general bio-innovation process.”

Andrea Traversone, Managing Partner at Amadeus Capital Partners, added, “Nuclera’s eProtein platform unites the very fragmented workflow that currently exists in proteomics. Nuclera is bringing rapid prototyping—a concept that did not exist until now—to biotech, and by speeding up research and opening up completely new avenues of innovation, it will have a far-reaching impact in numerous markets. We have been very impressed with the quality of the team that Michael and his co-founders have assembled and the unique technology they are developing.” 


About Nuclera

Nuclera is the leading pioneer in making biology accessible through its eProtein™ desktop bioprinting technology. Headquartered in Cambridge, UK, Nuclera was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to 60 employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins. Three exciting Nuclera technologies protected by 45+ patents enable Nuclera’s desktop bioprinter: eProtein™ synthesis, eDNA™ synthesis, and eDrop™ digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform creates an unprecedented one-stop shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers.



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.